AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Booz Allen, you need to believe it can keep turning its federal relationships and technical expertise into resilient earnings, even as funding and procurement remain uneven. The near term catalyst is its push into AI-enabled cyber products, while the biggest risk is that slower government spending and project delays continue to weigh on revenue and profit trends. The latest Vellox Ranger launch and softer Q1 FY2027 results do not materially change those core issues.
Among the recent announcements, the universal shelf registration stands out here, because it gives Booz Allen more flexibility to raise capital across debt and equity if needed. That flexibility could matter if AI-heavy offerings like Vellox Ranger and the broader Vellox suite require further investment at a time when earnings have come under pressure, potentially affecting how quickly the company can scale its AI-driven cyber ambitions.
Yet even as AI products expand, the risk that prolonged federal funding delays continue to affect Booz Allen’s revenue timing is something investors should be aware of...
Read the full narrative on Booz Allen Hamilton Holding (it's free!)
Booz Allen Hamilton Holding's narrative projects $12.3 billion revenue and $779.5 million earnings by 2029. This requires 3.2% yearly revenue growth and an earnings decrease of $65.5 million from $845.0 million today.
Uncover how Booz Allen Hamilton Holding's forecasts yield a $78.91 fair value, a 13% upside to its current price.
Some of the most optimistic analysts were assuming revenue could reach about US$13.7 billion by 2029, yet Vellox Ranger and related cyber contracts may either strengthen that view or highlight how dependent such optimism is on continued federal tech spending and contract wins.
Explore 6 other fair value estimates on Booz Allen Hamilton Holding - why the stock might be worth over 2x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com